RxDoctor Payments Data

Sandeep Virk

Hospitalist · Birmingham, ALNPI 1578766564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novartis at 24.3% of the total. Reporting peaked in 2021 at $623 and has fallen 88.1% since, to $74 in 2025. Among hospitalist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,571in general payments, 2019–2025

Across 129 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$625
  • Johnson & Johnson$436
  • Pfizer$373
  • AbbVie$294
  • E.r. Squibb & Sons, L.L.C.$265
  • AstraZeneca$121
  • plus $457 from 12 others

What the payments were for

  • Food & beverage$2,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,571 in reported general payments places this provider in the 95th percentile of 265 hospitalist providers in Alabama.

See all hospitalist providers in Alabama

Medicare billing

Part B allowed, 2024
$93,467
Medicare patients
332
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,812
LinzessLinaclotide14$7,324
Albuterol Sulfate HfaAlbuterol Sulfate18$381
Pantoprazole Sodium33$220
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$184
Prednisone33$163
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$124
Losartan Potassium27$96
ClopidogrelClopidogrel Bisulfate13$93
Metoprolol Succinate14$79
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$73
Furosemide28$60
Cephalexin11$55
Atorvastatin Calcium12$49
Tramadol Hcl16$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$373$7,81213 claims
AbbVieLinzess$294$7,32414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 hospitalist providers in Alabama.

Other hospitalist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →